SCNI

Scinai Immunotherapeutics
SCNI

Overview Fund Trends Analyst Outlook Journalist POV

12 hedge funds and large institutions have $2.98M invested in Scinai Immunotherapeutics in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

more capital invested

Capital invested by funds: $ → $

less ownership

Funds ownership: →

less funds holding

Funds holding: →

less first-time investments, than exits

New positions opened: | Existing positions closed:

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
12
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

1
-$57K
2
-$55K
3
-$24K
4
DCM
DAFNA Capital Management
California
-$18K
5
UBS Group
UBS Group
Switzerland
-$4.92K
Name Holding Trade Value Shares
Change 		Change in
Stake
1
$2.4M
2
$180K
3
$140K
4
$112K
5
$73K
6
$44K
7
$14K
8
$8K
9
$6K
10
$6K
11
$3K
12
–
13
–
14
–